|
Arbutamine
|
DB01102 |
[Arbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in diagnosing the presence or absence of coronary artery disease in patients who cannot exercise adequately .] |
|
Sibutramine
|
DB01105 |
[Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.] |
|
{[(2,2-Dihydroxy-Ethyl)-(2,3,4,5-Tetrahydroxy-6-Phosphonooxy-Hexyl)-Amino]-Methyl}-Phosphonic Acid
|
DB02433 |
|
|
4-Hydroperoxy-2-Methoxy-Phenol
|
DB03764 |
|
|
4-(2-Thienyl)Butyric Acid
|
DB02434 |
|
|
2'-cytidylic acid
|
DB03765 |
|
|
Sertraline
|
DB01104 |
[Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as [Citalopram] and [Fluoxetine]. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.
Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.[A1846,A187075,T28]] |
|
Cytidine-5'-Triphosphate
|
DB02431 |
[Cytidine 5'-(tetrahydrogen triphosphate). A cytosine nucleotide containing three phosphate groups esterified to the sugar moiety. [PubChem]] |
|
RU90395
|
DB02432 |
|
|
5-methyl-2'-deoxypseudouridine
|
DB03763 |
|
|
Capecitabine
|
DB01101 |
[Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.] |
|
Dihydrolipoic Acid
|
DB03760 |
|
|
5-fluoro-2'-deoxyuridine-5'-monophosphate
|
DB03761 |
|
|
Trehalose-6-Phosphate
|
DB02430 |
|
|
Pimozide
|
DB01100 |
[A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)] |
|
N-hydroxyguanidine
|
DB03770 |
|
|
Neisseria meningitidis group c capsular oligosaccharide diphtheria crm197 protein conjugate antigen
|
DB14428 |
[Neisseria meningitidis group c capsular oligosaccharide diphtheria crm197 protein conjugate antigen is a vaccine.] |
|
Neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen
|
DB14427 |
[Neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen is a vaccine.] |
|
Neisseria meningitidis group w-135 capsular oligosaccharide diphtheria crm197 protein conjugate antigen
|
DB14429 |
[Neisseria meningitidis group w-135 capsular oligosaccharide diphtheria crm197 protein conjugate antigen is a vaccine.] |
|
Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) hemagglutinin antigen (propiolactone inactivated)
|
DB14424 |
[A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.
There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.] |